1. Increases in HPV-16/18 antibody avidity and HPV-specific memory B-cell response in mid-adult aged men post-dose three of the quadrivalent HPV vaccine
- Author
-
Martha Abrahamsen, Eduardo Lazcano-Ponce, Jorge Salmerón, Cheryl N. Miller, Troy J. Kemp, Kim Dunham, Bradley Sirak, Yuanji Pan, Ligia A. Pinto, Anna R. Giuliano, and Kimberly Isaacs-Soriano
- Subjects
Adult ,Male ,Antibody Affinity ,chemical and pharmacologic phenomena ,Antibodies, Viral ,Article ,Papillomavirus Vaccines ,Immune system ,Humans ,Medicine ,Avidity ,Memory B cell ,Aged ,B-Lymphocytes ,Human papillomavirus 16 ,Human papillomavirus 18 ,General Veterinary ,General Immunology and Microbiology ,biology ,business.industry ,ELISPOT ,Papillomavirus Infections ,Public Health, Environmental and Occupational Health ,Antibody titer ,virus diseases ,female genital diseases and pregnancy complications ,Vaccination ,Infectious Diseases ,Immunology ,biology.protein ,Molecular Medicine ,Antibody ,business - Abstract
Strong quantitative and functional antibody responses to the quadrivalent human papillomavirus (HPV) vaccine were reported in mid-adult aged men, but there are limited data on the avidity of the antibody response and the memory B-cell response following vaccination. Although circulating antibodies induced by vaccination are believed to be the main mediators of protection against infection, evaluation of avidity of antibodies and memory B cell responses are critical for a better understanding of the vaccine immunogenicity mechanisms. Both the modified enzyme-linked immunosorbent assay (ELISA) and the enzyme-linked immunosorbent spot (ELISpot) assay are tools to measure the humoral and cellular immune responses post vaccination to characterize vaccine immunogenicity. The avidity of HPV-16 and HPV-18 specific IgG in the serum of mid-adult aged men (N = 126) who received three quadrivalent HPV vaccine doses was examined using a modified ELISA. HPV-16 memory B-cell responses were assessed via ELISpot at month 0 (prior to vaccination) and 1-month post-dose three of the vaccine (month 7). The quadrivalent vaccine induced an increase in HPV-16 and HPV-18 antibody avidity at month 7. HPV-18 avidity levels moderately correlated with anti-HPV-18 antibody titers, but no association was observed for HPV-16 antibody titers and avidity levels. The HPV-16-specific memory B-cell response was induced following three vaccine doses, however, no association with anti-HPV-16 antibody avidity was observed. Three doses of quadrivalent HPV vaccine increased antibody affinity maturation for HPV-16/18 and increased the frequency of anti-HPV-16 memory B-cells in mid-adult aged men.
- Published
- 2021
- Full Text
- View/download PDF